Sex-independent neuroprotection with minocycline after experimental thromboembolic stroke

Experimental and Translational Stroke Medicine

Volumn 3, Issue 1, 2011, Pages

  Hoda, Md Nasrul ^a,b   Li, Weiguo ^a   Ahmad, Ajmal ^a   Ogbi, Safia ^a   Zemskova, Marina A ^a   Johnson, Maribeth H ^a   Ergul, Adviye ^a,b   Hill, William D ^a,b   Hess, David C ^a   Sazonova, Irina Y ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Animal model; Minocycline; MMP 9; Neuroprotection; Sex; Thromboembolic stroke

Indexed keywords

GELATINASE B; MINOCYCLINE; NEUROPROTECTIVE AGENT;

AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; FEMALE; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE;

EID: 84863133783     PISSN: None     EISSN: 20407378     Source Type: Journal    
DOI: 10.1186/2040-7378-3-16     Document Type: Article

References (41)

1. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD. Gender-linked brain injury in experimental stroke. Stroke 1998, 29(1):159-165. discussion 66, 10.1161/01.STR.29.1.159, 9445346.
2. Brait VH, Jackman KA, Walduck AK, Selemidis S, Diep H, Mast AE, Guida E, Broughton BR, Drummond GR, Sobey CG. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J Cereb Blood Flow Metab 2010, 30(7):1306-1317. 10.1038/jcbfm.2010.14, 2949221, 20145655.
3. Liu F, McCullough LD. Middle cerebral artery occlusion model in rodents: methods and potential pitfalls. J Biomed Biotechnol 2011, 2011:464701. 3035178, 21331357.
4. Alkayed NJ, Murphy SJ, Traystman RJ, Hurn PD, Miller VM. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke 2000, 31(1):161-168. 10.1161/01.STR.31.1.161, 10625733.
5. McCullough LD, Zeng Z, Blizzard KK, Debchoudhury I, Hurn PD. Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab 2005, 25(4):502-512. 10.1038/sj.jcbfm.9600059, 15689952.
6. Zeynalov E, Nemoto M, Hurn PD, Koehler RC, Bhardwaj A. Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide. J Cereb Blood Flow Metab 2006, 26(3):414-420. 10.1038/sj.jcbfm.9600196, 16049424.
7. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH, . STAIR Group Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations. Stroke 2009, 40(6):2244-2250. 10.1161/STROKEAHA.108.541128, 2888275, 19246690, STAIR Group.
8. Liu S, Zhen G, Meloni BP, Campbell K, Winn HR. Rodent Stroke Model Guidelines for Preclinical Stroke Trials (1st Edition). J Exp Stroke Transl Med 2009, 2(2):2-27. 2848489, 20369026.
9. del Zoppo GJ. Clinical trials in acute stroke: why have they not been successful?. Neurology 1998, 51(3 Suppl 3):S59-61.
10. Zhang Z, Chopp M, Zhang RL, Goussev A. A mouse model of embolic focal cerebral ischemia. J Cereb Blood Flow Metab 1997, 17(10):1081-1088.
11. Wang X, Xu L, Wang H, Grzanna R, Zhan Y, Knabb RM, Luettgen JM, Bozarth TA, Galemmo RA, Wong PC, Bernard R, Vargas H, Chopp M, Friedman SM, Feuerstein GZ. Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats. Stroke 2003, 34(2):468-474. 10.1161/01.STR.0000049765.81774.A3, 12574562.
12. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002, 33(11):2711-2717. 10.1161/01.STR.0000033932.34467.97, 12411666.
13. Kriz J, Gowing G, Julien JP. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol 2003, 53(4):429-436. 10.1002/ana.10500, 12666110.
14. Machado LS, Sazonova IY, Kozak A, Wiley DC, El-Remessy AB, Ergul A, Hess DC, Waller JL, Fagan SC. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke 2009, 40(9):3028-3033. 10.1161/STROKEAHA.109.556852, 2754038, 19628804.
15. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 2008, 39(12):3372-3377. 10.1161/STROKEAHA.108.514026, 18927459.
16. Wang CX, Yang T, Noor R, Shuaib A. Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol 2002, 2:2. 10.1186/1471-2377-2-2, 107740, 11960560.
17. Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, Hill WD, Feuerstein G, Hess DC. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol 2004, 4:7. 10.1186/1471-2377-4-7, 415551, 15109399.
18. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke 2006, 37(4):1087-1093. 10.1161/01.STR.0000206281.77178.ac, 16497985.
19. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999, 96(23):13496-13500. 10.1073/pnas.96.23.13496, 23976, 10557349.
20. Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, Hall CE, Switzer JA, Ergul A, Hess DC. Minocycline to Improve Neurologic Outcome in Stroke (MINOS). A Dose-Finding Study. Stroke 2010, 41(10):2283-2287. 10.1161/STROKEAHA.110.582601, 20705929.
21. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, Anca-Hershkowitz M, Sadeh M. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007, 69(14):1404-1410. 10.1212/01.wnl.0000277487.04281.db, 17909152.
22. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006, 103(25):9685-9690. 10.1073/pnas.0600554103, 1480467, 16769901.
23. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci 2006, 7:56. 10.1186/1471-2202-7-56, 1543649, 16846501.
24. Li J, McCullough LD. Sex differences in minocycline-induced neuroprotection after experimental stroke. J Cereb Blood Flow Metab 2009, 29(4):670-674. 10.1038/jcbfm.2009.3, 2855881, 19190654.
25. Liu F, Li Z, Li J, Siegel C, Yuan R, McCullough LD. Sex Differences in Caspase Activation After Stroke. Stroke 2009, 40(5):1842-1848. 10.1161/STROKEAHA.108.538686, 2674515, 19265047.
26. Nelson JF, Felicio LS, Randall PK, Sims C, Finch CE. A longitudinal study of estrous cyclicity in aging C57BL/6J mice: I. Cycle frequency, length and vaginal cytology. Biol Reprod 1982, 27(2):327-339. 10.1095/biolreprod27.2.327, 6889895.
27. Zhang Z, Zhang RL, Jiang Q, Raman SB, Cantwell L, Chopp M. A new rat model of thrombotic focal cerebral ischemia. J Cereb Blood Flow Metab 1997, 17(2):123-135.
28. Ergul A, Elgebaly MM, Middlemore ML, Li W, Elewa H, Switzer JA, Hall C, Kozak A, Fagan SC. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol 2007, 7:33. 10.1186/1471-2377-7-33, 2098774, 17937795.
29. Li W, Kelly-Cobbs AI, Mezzetti EM, Fagan SC, Ergul A. Endothelin-1-mediated cerebrovascular remodeling is not associated with increased ischemic brain injury in diabetes. Can J Physiol Pharmacol 2010, 88(8):788-795. 10.1139/Y10-040, 20725136.
30. Sugawara J, Hayashi K, Kurachi S, Tanaka T, Yokoi T, Kurachi K. Age-related effects of regular physical activity on hemostatic factors in men. J Thromb Thrombolysis 2008, 26(3):203-210. 10.1007/s11239-007-0092-y, 17828598.
31. Stout RW, Crawford VL, McDermott MJ, Rocks MJ, Morris TC. Seasonal changes in haemostatic factors in young and elderly subjects. Age Ageing 1996, 25(3):256-258. 10.1093/ageing/25.3.256, 8670564.
32. Lacroix KA, Bean C, Box L, Wagner K. A study of the fibrinolytic response in healthy men and women following a brief exposure to venous occlusion. Thromb Res 1996, 81(1):133-143. 10.1016/0049-3848(95)00221-9, 8747528.
33. Savitz SI, Schlaug G, Caplan L, Selim M. Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke. Stroke 2005, 36(7):1447-1451. 10.1161/01.STR.0000170647.42126.a8, 15947268.
34. Dinapoli VA, Rosen CL, Nagamine T, Crocco T. Selective MCA occlusion: a precise embolic stroke model. J Neurosci Methods 2006, 154(1-2):233-238. 10.1016/j.jneumeth.2005.12.026, 16472870.
35. Sanchez C, Alonso de Lecinana M, Diez-Tejedor E, Carceller F, Vega A, Roda JM. Treatment of embolic cerebral infarct via thrombolysis and cytoprotection with U-74389-G in rats. Rev Neurol 1998, 27(158):653-658.
36. Heo JH, Kim SH, Lee KY, Kim EH, Chu CK, Nam JM. Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 2003, 34(6):e48-50. 10.1161/01.STR.0000073788.81170.1C, 12750540.
37. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003, 34(9):2165-2170. 10.1161/01.STR.0000088062.86084.F2, 12907822.
38. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001, 32(12):2762-2767. 10.1161/hs1201.99512, 11739970.
39. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabín J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003, 107(4):598-603. 10.1161/01.CIR.0000046451.38849.90, 12566373.
40. Montaner J, Rovira A, Molina CA, Arenillas JF, Ribo M, Chacon P, Monasterio J, Alvarez-Sabín J. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab 2003, 23(12):1403-1407.
41. Switzer JA, Hess DC, Ergul A, Waller JL, Machado LS, Portik-Dobos V, Pettigrew LC, Clark WM, Fagan SC. Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke. Stroke 2011, 42(9):2633-2633. 10.1161/STROKEAHA.111.618215, 21737808.